SGLT2 Inhibitors for Preserved Ejection Fraction (HFpEF)
A significant breakthrough in 2026 is the widespread use of Empagliflozin and Dapagliflozin for patients with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).
Historically, these patients had few treatment options. In 2026, SGLT2 inhibitors are the first medications proven to reduce the risk of cardiovascular death and hospital admission in this group. They are now standard prescriptions for nearly all heart failure patients, regardless of their heart's pumping strength (ejection fraction).
2 Views